Skip to main content

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial

Intervista a Roy S. Herbst By 4 Giugno 2023No Comments

At ASCO 2023 Roy S. Herbst (Yale School of Medicine and Yale Cancer Center) presented the Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).